Tier 4 — Small Volume Parenterals

Opportunity — substitute 20-40% of the USD 800M-1B annual import bill. Target WHO-GMP-compliant production of human medicines for infectious and non-infectious diseases including anti-TB, anti-cancer, ARVs, first-line anti-malarials.▸Market assurance — 15% MSD procurement preference; framework agreements; ...

Tier 2 — API & Excipients Manufacturing▸Opportunity — zero API manufacturing capacity in the entire EAC region; 100% of APIs currently imported.▸Strategic priority — designated by TMDA and PIAT as a medium-to-long-term focus; highest policy priority.▸Investment range — USD 50-200M for scaled API produc...

Shanghai, 15 June 2026 — A delegation from Tanzania's Pharmaceutical Investment Acceleration Taskforce (PIAT), the Government's whole-of-government mechanism for fast-tracking strategic pharmaceutical investment, has arrived in Shanghai for CPHI China 2026, held at the Shanghai New International Expo Center from 16 to 18 June. The delegation will engage directly with international manufacturers, active pharmaceutical ingredient (API) producers, and contract manufacturing organisations to present Tanzania's case as Africa's next pharmaceutical manufacturing hub.
CPHI China is Asia's leading pharmaceutical trade event, convening suppliers and buyers across the entire supply chain — making it a natural venue for Tanzania's outreach to the manufacturers best positioned to establish production capacity on the continent.

"Tanzania is ready to become Africa's pharmaceutical manufacturing hub. The direction is clear. The commitment is firm. The time is now,"